Northern Trust’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Northern Trust’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-58,119	Closed	-$10K	–	4764
2022 Q3	$10K	Hold	58,119	–	–	﹤0.01%	4646
2022 Q2	$35K	Hold	58,119	–	–	﹤0.01%	4518
2022 Q1	$77K	Sell	58,119 -4,587	-7%	-$7.44K	﹤0.01%	4429
2021 Q4	$164K	Hold	62,706	–	–	﹤0.01%	4265
2021 Q3	$195K	Sell	62,706 -1,775	-3%	-$5.92K	﹤0.01%	4196
2021 Q2	$240K	Sell	64,481 -102,783	-61%	-$342K	﹤0.01%	4076
2021 Q1	$579K	Buy	167,264 +1,924	+1%	+$7.81K	﹤0.01%	3768
2020 Q4	$556K	Sell	165,340 -1,599	-1%	-$5.72K	﹤0.01%	3699
2020 Q3	$586K	Buy	166,939 +316	+0.2%	+$1.27K	﹤0.01%	3569
2020 Q2	$766K	Sell	166,623 -4,458	-3%	-$19.7K	﹤0.01%	3440
2020 Q1	$566K	Buy	171,081 +28,688	+20%	+$131K	﹤0.01%	3417
2019 Q4	$870K	Sell	142,393 -13,027	-8%	-$53.7K	﹤0.01%	3437
2019 Q3	$648K	Buy	155,420 +118,393	+320%	+$944K	﹤0.01%	3494
2019 Q2	$486K	Buy	+37,027	New	+$454K	﹤0.01%	3557

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northern Trust's PHAS Position: Q4 2022 in Review

Northern Trust sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 58,119 shares — an estimated $10K sold.

Northern Trust first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $870K in Q4 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Northern Trust reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Northern Trust sold 58,119 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $10K.
Northern Trust first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
Northern Trust's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $870K in Q4 2019.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Northern Trust's 13F filing for Q4 2022, filed 13 Feb 2023.